Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03736863 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

StatusUnknown
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Enrollment target: 125 to 147v9 Show 6 more changesShow less
    • Study completion date: Dec 30, 2024 to Dec 30, 2025
    • Interventions: Apatinib+ SHR-1210（Camrelizumab） (Drug), Apatinib+ SHR-1316（Adebrelimab） (Drug) to Apatinib+ SHR-1210（Camrelizumab） (Drug), Apatinib+ SHR-1316（Adebrelimab） (Drug), SHR-1316（Adebrelimab）+SHR-A2009 (Drug)
    • Study description shortened, about 33 words
    • Study arms: 3 to 4
    • Eligibility criteria shortened, about 4 words
    • Study title expanded, about 5 words
  3. Enrollment target: 85 to 125v8 Show 5 more changesShow less
    • Study completion date: Feb 28, 2023 to Dec 30, 2024
    • Interventions: Apatinib+ SHR-1210（Camrelizumab） (Drug) to Apatinib+ SHR-1210（Camrelizumab） (Drug), Apatinib+ SHR-1316（Adebrelimab） (Drug)
    • Study description expanded, about 8 words
    • Study arms: 1 to 3
    • Study title shortened, about 1 word
  4. Study completion date: Dec 31, 2022 to Feb 28, 2023v7
  5. Enrollment target: 52 to 85
    • Study completion date: Dec 31, 2021 to Dec 31, 2022
    • Eligibility criteria expanded, about 22 words
    • Study description revised
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Enrollment target: 45 to 52v5 Show 5 more changesShow less
    • Primary completion date changed from estimate of Dec 2020 to Jun 20, 2021
    • Study completion date: Apr 2021 to Dec 31, 2021
    • Interventions: Apatinib+SHR-1210 (Drug) to Apatinib+ SHR-1210（Camrelizumab） (Drug)
    • Eligibility criteria expanded, about 119 words
    • Secondary endpoints: 5 to 8
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Apr 2020 to Dec 2020
    • Start date changed from estimate of Apr 2019 to Dec 5, 2019
    • Site details revised
    v4
  3. Start date: Feb 2019 to Apr 2019
    • Primary completion date: Feb 2020 to Apr 2020
    • Study completion date: Feb 2021 to Apr 2021
    v3
  4. Start date: Dec 2018 to Feb 2019
    • Primary completion date: Dec 2019 to Feb 2020
    • Study completion date: Dec 2020 to Feb 2021
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to observe and evaluate the efficacy and safety of multiple drug combinations in the treatment of advanced esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT03736863
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions
(from sponsor)		 Esophageal Cancer
Related terms Esophageal Neoplasms
Enrollment 147 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov